
The European Commission—the EU's executive arm—said that the sale fully addresses officials' earlier concerns that the deal could hinder competition in tampon markets in Czechia, Estonia, and Slovakia.
Kenvue Inc. is a consumer health company globally.
| Revenue (TTM) | $15.41B |
| Gross Profit (TTM) | $9.00B |
| EBITDA | $3.48B |
| Operating Margin | 19.40% |
| Return on Equity | 15.60% |
| Return on Assets | 6.99% |
| Revenue/Share (TTM) | $8.04 |
| Book Value | $5.50 |
| Price-to-Book | 3.22 |
| Price-to-Sales (TTM) | 2.36 |
| EV/Revenue | 2.69 |
| EV/EBITDA | 12.89 |
| Quarterly Earnings Growth (YoY) | 8.50% |
| Quarterly Revenue Growth (YoY) | 3.00% |
| Shares Outstanding | $1.92B |
| Float | $1.92B |
| % Insiders | 0.08% |
| % Institutions | 95.84% |
Volatility is currently contracting

The European Commission—the EU's executive arm—said that the sale fully addresses officials' earlier concerns that the deal could hinder competition in tampon markets in Czechia, Estonia, and Slovakia.

DALLAS, Oct. 13, 2026 /PRNewswire/ -- Kimberly-Clark Corporation (NASDAQ: KMB) ("Kimberly-Clark") announced today that the requisite number of consents have been received to adopt certain proposed amendments (the "Amendments") with respect to all outstanding notes of Kenvue Inc. (NYSE: KVUE) ("Kenvue"). The results are based on (i) early tenders in the offers to exchange (each an "Exchange Offer" and, collectively, the "Exchange Offers") any and all outstanding notes (the "Kenvue Notes") issued by Kenvue for up to $7,000,000,000 aggregate principal amount of new notes to be issued by Kimberly-Clark (the "Kimberly-Clark Notes") and cash and (ii) related consent solicitations (each, a "Consent Solicitation" and, collectively, the "Consent Solicitations") being made by Kimberly-Clark on behalf of Kenvue to adopt the Amendments to the indenture (the "Kenvue Indenture") governing the Kenvue Notes.

While nervous investors obsess over a handful of tech giants propping up the whole market, one portfolio manager keeps funneling fresh cash into the brands sitting in every American medicine cabinet, and the reasoning might make you rethink your own

Investors looking for stocks in the Consumer Products - Staples sector might want to consider either Newell Brands (NWL) or Kenvue (KVUE). But which of these two stocks is more attractive to value investors?

Russ Torres to Depart Kimberly-Clark for External CEO Role Carlos De Jesus to be Appointed as President, North America and Leonardo Curado to be Appointed as President, EMEA After Kenvue Acquisition DALLAS, Oct. 1, 2026 /PRNewswire/ -- Kimberly-Clark Corporation (NASDAQ: KMB) today announced planned executive transitions and updates to the future leadership team for the company upon completion of its pending acquisition of Kenvue Inc. (NYSE: KVUE), which is expected in the fourth quarter of 2026. Russ Torres, President and Chief Operating Officer of Kimberly-Clark, and Head of the Integration Management Office (IMO), will leave the company to assume an external CEO role.

Kimberly-Clark (NASDAQ:KMB | KMB Price Prediction) pays a quarterly dividend of $1.28 per share. That is an annualized forward rate of $5.12 and a yield of 5.16%.

DALLAS, Sept. 28, 2026 /PRNewswire/ -- Kimberly-Clark Corporation (NASDAQ: KMB) ("Kimberly-Clark") announced today the commencement, in connection with its previously announced pending acquisition ("Acquisition") of Kenvue Inc. (NYSE: KVUE) ("Kenvue"), of an exchange offer (each an "Exchange Offer" and, collectively, the "Exchange Offers") for any and all outstanding notes (the "Kenvue Notes") issued by Kenvue for up to $7,000,000,000 aggregate principal amount of new notes to be issued by Kimberly-Clark (the "Kimberly-Clark Notes") and cash.

Kimberly-Clark has offered concessions to address EU antitrust concerns about its $40 billion bid for Tylenol maker Kenvue , a filing on the European Commission website showed on Wednesday.

While investors pile into pricey AI darlings, a handful of battle-tested Dividend Kings have quietly slipped to levels that scream value, and Wall Street analysts see serious upside ahead for 2027.

Johnson & Johnson has raised its dividend for 64 straight years, but faces billions in talc-related litigation liabilities. Kenvue offers a higher yield of 4.71%, but its pending acquisition by Kimberly-Clark creates uncertainty about its dividend outlook.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on KVUE and any ticker you trade — then tracks every position and per-strategy win rate.